Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Open accessThe DOI matches its Crossref record; 793 of the 793 references it cites were found in a registry or an index; 233 of the 632 sources its claims cite were checked for support.
Abstract
The human gastrointestinal tract is populated with a diverse microbial community. The vast genetic and metabolic potential of the gut microbiome underpins its ubiquity in nearly every aspect of human biology, including health maintenance, development, aging, and disease. The advent of new sequencing technologies and culture-independent methods has allowed researchers to move beyond correlative studies toward mechanistic explorations to shed light on microbiome–host interactions. Evidence has unveiled the bidirectional communication between the gut microbiome and the central nervous system, referred to as the “microbiota–gut–brain axis”. The microbiota–gut–brain axis represents an important regulator of glial functions, making it an actionable target to ameliorate the development and progression of neurodegenerative diseases. In this review, we discuss the mechanisms of the microbiota–gut–brain axis in neurodegenerative diseases. As the gut microbiome provides essential cues to microglia, astrocytes, and oligodendrocytes, we examine the communications between gut microbiota and these glial cells during healthy states and neurodegenerative diseases. Subsequently, we discuss the mechanisms of the microbiota–gut–brain axis in neurodegenerative diseases using a metabolite-centric approach, while also examining the role of gut microbiota-related neurotransmitters and gut hormones. Next, we examine the potential of targeting the intestinal barrier, blood–brain barrier, meninges, and peripheral immune system to counteract glial dysfunction in neurodegeneration. Finally, we conclude by assessing the pre-clinical and clinical evidence of probiotics, prebiotics, and fecal microbiota transplantation in neurodegenerative diseases. A thorough comprehension of the microbiota–gut–brain axis will foster the development of effective therapeutic interventions for the management of neurodegenerative diseases.
Overview
CoChat Summary
TL;DR
This review synthesizes mechanistic and therapeutic evidence on the microbiota–gut–brain axis in neurodegenerative diseases, emphasizing bidirectional communication between gut microbiota and glial cells (microglia, astrocytes, oligodendrocytes). It argues that gut-derived metabolites, neurotransmitters, and hormones modulate glial function via the intestinal barrier, blood–brain barrier, meninges, and peripheral immune system, and assesses probiotics, prebiotics, and FMT as therapeutic strategies.
Key findings
- The gut microbiome regulates microglial maturation and function largely via short-chain fatty acids (SCFAs); germ-free and antibiotic-treated mice show impaired microglial immune responses that are partially restored by recolonization or SCFA supplementation. Among neuronal and glial cells, microglia are described as the most vulnerable to gut microbiome alterations.
- In AD models, germ-free or antibiotic-treated APP/PS1 and 5xFAD mice show reduced Aβ pathology and microglial activation, and FMT from AD patients or conventionally raised mice restores pathology; effects are sex-dependent (e.g., absent in female APP/PS1-21 mice). In PD, germ-free/antibiotic-treated α-synuclein-overexpressing mice show less pathology, and FMT from PD patients restores motor dysfunction.
- Metabolite-centric evidence is context-dependent: SCFAs are largely neuroprotective in PD but show conflicting (both protective and detrimental) effects in AD; TMAO promotes microglial/astrocytic activation and Aβ/tau pathology; secondary bile acids UDCA/TUDCA are neuroprotective; indole derivatives act via AHR; BCAAs promote anti-inflammatory microglial phenotypes; nicotinamide (NAM) is reduced in ALS serum and CSF.
- Clinical translation is mixed: probiotics/prebiotics improve constipation-related parameters and some cognitive/motor scores in PD and MCI trials, but several AD trials show no significant cognitive benefit; the paper notes a 95% positive-result rate in human microbiota-associated rodent studies warrants caution.
Methods
- Narrative review (not a primary study) covering mechanisms of the microbiota–gut–brain axis in AD, PD, ALS, HD, and FTD, with emphasis on glial interactions.
- Synthesizes preclinical (germ-free, antibiotic-treated, FMT, transgenic mouse models) and clinical evidence, including tables of in vivo probiotic/prebiotic/FMT studies and completed/ongoing clinical trials (Tables 1–5).
- Uses a metabolite-centric framing (SCFAs, bile acids, TMAO, tryptophan/indoles, PUFAs, BCAAs, NAM) plus gut microbiota-related neurotransmitters (serotonin, GABA, dopamine, acetylcholine, glutamate) and gut hormones (ghrelin, leptin, GLP-1).
Limitations
- Stated: establishing causality between altered gut microbiome and disease is difficult (causative vs. consequential vs. bystander); animal models do not fully recapitulate human microbiome/pathobiology; the 95% positive-result rate in human microbiota-associated rodents demands caution against overstating causal claims.
- Stated: many SCFA studies reporting detrimental effects used germ-free mice, which are physiologically abnormal, limiting extrapolation to humans; heterogeneity across AD mouse models complicates predicting SCFA implications.
- Stated: clinical trials often lack gut microbiome profiling, limiting pre/post comparison; few trials exist in ALS, FTD, and HD; FMT is limited by variable engraftment, limited scalability, lack of standardized protocols, and pathogen-transmission risk. Evident from the text: much of the mechanistic evidence is preclinical, and several findings (e.g., TMAO in PD, astrocyte studies relying on GFAP densitometry) are explicitly described as conflicting or methodologically limited.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
111 Valid · 10 Not valid · 252 Not checked · 37 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Ultimately, the activation of microglia by these protein aggregates creates a feed-forward vicious cycle that aggravates neurodegeneration as activated microglia contribute to the propagation of tau, Aβ, α-synuclein, and TDP-43 into unaffected brain regions.159–164”
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > Roles of microglia in neurodegenerative diseases > Microglia-mediated neuroinflammation
What the sources say
- Partly supportedcites [159] Brelstaff, J. H. et al. Microglia become hypofunctional and release metalloproteases and tau seeds when phagocytosing live neurons with P301S tau aggregates. Sci. Adv. 7, eabg4980 (2021). sourceExperimental — accuracy not yet measured
The Discussion (Fig. 7; page not available in our copy) proposes a self-amplifying cycle in which microglia that phagocytose tau-bearing neurons release tau seeds that induce further aggregation. The Introduction describes microglia as possible vectors of tau spread in the local environment. The paper does not establish microglial propagation of Aβ, α-synuclein, or TDP-43, or demonstrate spread into unaffected brain regions. (LLM, conf=0.88)
- Supportedcites [160] d’Errico, P. et al. Microglia contribute to the propagation of Aβ into unaffected brain tissue. Nat. Neurosci. 25, 20–25 (2022). source
The Main section says microglia become reactive around Aβ plaques and carry Aβ into previously unaffected brain tissue. The Abstract likewise reports that microglia carry Aβ pathology into unaffected tissue. In this multi-citation sentence, this paper supports the Aβ-propagation component; it is not evidence for propagation of the other named proteins. (LLM, conf=0.90)
- Partly supportedcites [161] George, S. et al. Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson’s disease. Mol. Neurodegener. 14, 34 (2019). sourceExperimental — accuracy not yet measured
The Background describes a proposed vicious cycle in which aggregated α-synuclein activates microglia and inflammatory mediators promote further α-synuclein aggregation. The Discussion reports increased α-synuclein transfer to grafted neurons after LPS-induced microglial activation. The paper does not establish that activated microglia propagate tau, Aβ, or TDP-43 into unaffected brain regions; its transfer findings concern α-synuclein in a mouse transplantation model. (LLM, conf=0.88)
- Partly supportedcites [162] Pascoal, T. A. et al. Microglial activation and tau propagate jointly across Braak stages. Nat. Med. 27, 1592–1599 (2021). sourceExperimental — accuracy not yet measured
The Discussion reports that microglial activation and tau spread together across brain regions, with Aβ potentiating the effect of microglial activation on tau spread. It does not establish that activated microglia propagate Aβ, α-synuclein, or TDP-43, or demonstrate the claimed feed-forward vicious cycle. The paper also frames its human findings as associations rather than proof of that causal cycle. (LLM, conf=0.88)
- Supportedcites [163] Guo, M. et al. Microglial exosomes facilitate α-synuclein transmission in Parkinson’s disease. Brain 143, 1476–1497 (2020). source
For this multi-cited sentence, the paper supports the α-synuclein portion. The Introduction reports that α-synuclein activates microglia and that their inflammatory cytokines enhance exosome-induced aggregation and spreading; the Results also report that microglial inflammation accelerated α-synuclein transmission. This paper is not being treated as evidence for every protein named in the sentence. (LLM, conf=0.88)
- Disputedcites [164] Svahn, A. J. et al. Nucleo-cytoplasmic transport of TDP-43 studied in real time: impaired microglia function leads to axonal spreading of TDP-43 in degenerating motor neurons. Acta Neuropathol. 136, 445–459 (2018). sourceExperimental — accuracy not yet measured
The Discussion says normal microglia prevent TDP-43 spreading by engulfing injured motor neurons; axonal and extracellular spreading occurred when functional microglia were depleted. That is contrary to the claim that activated microglia propagate TDP-43. The cited paper does not establish the claim about tau, Aβ, or α-synuclein. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Similarly, the gut microbiota is required for microglial activation in 5xFAD mice.203–205”
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > Microbiota–gut–brain axis in neurodegenerative diseases > Interaction between gut microbiota and microglia
What the sources say
- Supportedcites [203] Wang, X. et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res. 29, 787–803 (2019). source
The Results section headed 'Gut microbiota is required for immune cell infiltration and microglial activation in the brain' states that gut-microbiota ablation by an antibiotic cocktail in 5XFAD transgenic (Tg) mice produced a marked reduction in microbial abundance along with a reduction in both infiltrating pro-inflammatory Th1 cells and M1 microglia in the brain. Fig. 2's legend ('The gut microbiota is required for immune cell infiltration and microglial activation', five-month oral gavage of ABX in 7-month-old 5XFAD Tg mice) and the Discussion ('dysbiosis of the gut microbiota is required for the infiltration of various peripheral immune cells... gut dysbiosis promotes Th1 cell infiltration... and in turn triggers the microglia differentiation towards a pro-inflammatory state') restate the same point, matching the claim's population (5xFAD mice) and conclusion. (LLM, conf=0.92)
- Partly supportedcites [204] Chen, C. et al. Gut dysbiosis contributes to amyloid pathology, associated with C/EBPβ/AEP signaling activation in Alzheimer’s disease mouse model. Sci. Adv. 6, eaba0466 (2020). sourceExperimental — accuracy not yet measured
Our copy does contain a relevant own-data result: in the Results section 'Antibiotic treatment represses C/EBPβ/AEP signaling in 5xFAD mice, alleviating AD pathologies', chronic ABX depletion of the gut microbiota lowered the microglial marker signal ('Positive signals from Iba-1, a microglia/macrophage-specific calcium-binding protein as microglia marker, were reduced upon ABX treatment (fig. S3E)'), so the direction of the claim (microbiota loss dampens microgliosis in 5xFAD) is present. However, the paper never states that the microbiota is 'required' for microglial activation, and it reports only a marker-density change, not activation phenotyping; the causal microbiota-to-microglia conclusion it invokes is credited to other works in the Discussion (Minter et al., ref 10, for reduced Aβ deposition and associated gliosis; Dodiya et al., ref 41, for fecal transplant partially restoring Aβ pathology and microglial morphology in APP/PS1-21, not 5xFAD). The remaining prompt passages characterize dysbiosis in 5xFAD stool (Fig. 1, fig. S1) and say nothing about microglia. (LLM, conf=0.72)
- Disputedcites [205] Mezö, C. et al. Different effects of constitutive and induced microbiota modulation on microglia in a mouse model of Alzheimer’s disease. Acta Neuropathol. Commun. 8, 119 (2020). sourceExperimental — accuracy not yet measured
Our copy never states that microbiota is required for microglial activation in 5xFAD mice; it frames the relationship as modulation, and its data run the other way. In Results 'Permanent absence of microbes alters microglial gene profile in GF 5xFAD mice' the authors report UPREGULATED AD-associated activation markers (Apoe, Trem2, Axl, Cst7, Itgax/CD11c, Cd9, Clec7a, with reduced P2ry12) in microglia from germ-free 5xFAD mice, concluding the AD-linked activation signature 'can be modulated by host microbiota'. The Discussion likewise describes 'a certain microbiota-dependent influence on this microglial activation state' and increased microglial density, plaque association and Aβ uptake under GF conditions, while only neuroinflammation/chemokine signaling pathways were diminished — i.e., activation occurs in the absence of microbiota, not as a microbiota-required phenomenon. (LLM, conf=0.75)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Although studies in AD patients have yielded slightly heterogeneous results in BA composition, they have reported a consistent pattern of reduced levels of primary BAs and elevated levels of secondary BAs.”
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > Gut microbiota-derived metabolites in neurodegenerative diseases > Bile acids regulate neuroinflammation and neurodegeneration
What the sources say
- Partly supportedcites [355] Baloni, P. et al. Metabolic network analysis reveals altered bile acid synthesis and metabolism in Alzheimer’s disease. Cell Rep. Med. 1, 100138 (2020). sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says increased secondary bile acid levels and increased ratios to primary bile acids have been linked to AD. The Results (page unavailable) report higher ratios to cholic acid for several secondary bile acids in AD brain samples, but also for primary bile acids including CDCA and TCA. These ratios do not establish a consistent reduction in primary bile acid levels. (LLM, conf=0.86)
- Partly supportedcites [356] MahmoudianDehkordi, S. et al. Altered bile acid profile associates with cognitive impairment in Alzheimer’s disease—an emerging role for gut microbiome. Alzheimers Dement. 15, 76–92 (2019). sourceExperimental — accuracy not yet measured
The Results section reports lower levels of one primary bile acid (CA) and higher levels of DCA and several secondary bile acids in AD patients. The Discussion notes that an earlier study did not find a significant decrease in CA, so the source does not establish a consistent reduction in primary bile acids across studies. (LLM, conf=0.86)
- Partly supportedcites [357] Nho, K. et al. Altered bile acid profile in mild cognitive impairment and Alzheimer’s disease: relationship to neuroimaging and CSF biomarkers. Alzheimers Dement. 15, 232–244 (2019). sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports that increased secondary bile acids and higher secondary-to-primary bile acid ratios were associated with AD and poor cognition. It does not report reduced primary bile acid levels in AD patients, so it does not establish the claimed consistent pattern across studies. (LLM, conf=0.84)
- Disputedcites [358] Varma, V. R. et al. Bile acid synthesis, modulation, and dementia: a metabolomic, transcriptomic, and pharmacoepidemiologic study. PLoS Med. 18, e1003615 (2021). sourceExperimental — accuracy not yet measured
The Results (Step 3; page unavailable) report marginally higher, not lower, concentrations of the primary bile acids CA and CDCA in AD brain samples than in controls, although the difference was nonsignificant. The Discussion reports a previous study finding lower plasma CA in AD and a higher secondary-to-primary bile-acid ratio associated with cognitive impairment, but neither establishes the claimed consistent pattern of reduced primary and elevated secondary bile-acid levels. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Moreover, studies on animal models have provided compelling evidence that the altered gut microbiome drives neurodegenerative disease pathogenesis, primarily through the modulation of microglial functions and activation.54–57”
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > Introduction
What the sources say
- Partly supportedcites [54] Dodiya, H. B. et al. Gut microbiota-driven brain Aβ amyloidosis in mice requires microglia. J. Exp. Med. 219, e20200895 (2022). sourceExperimental — accuracy not yet measured
Our copy supports the core of the attribution: the Abstract and the Results section 'Microglia play an essential role in mediating short-term ABX-perturbed microbiome's effect on Aβ amyloidosis' establish causality between an antibiotic-perturbed gut microbiota, microglia, Aβ and neurodegeneration, and the Introduction states that microglial depletion with PLX5622 'argues for an essential role of microglia in mediating microbiome-driven brain amyloidosis'. However, that causal demonstration is confined to Aβ amyloidosis in male APPPS1-21 mice (the Introduction repeatedly notes the effects are 'specific to male animals'), whereas the citing sentence extends it to neurodegenerative disease pathogenesis in general; for the other disorders it lists (PD, MS, brain injury, stroke) the source only says a dysfunctional microbiota–brain axis 'might play an important role' and that the gut microbiome 'potentially' affects neurodegeneration. The 'primarily through modulation of microglial functions and activation' mechanism is also not settled by the source, which states in the Discussion that 'the mechanism(s) underlying this fascinating result remains to be established' while offering scenarios. (LLM, conf=0.75)
- Partly supportedcites [55] Sampson, T. R. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell 167, 1469–1480.e1412 (2016). sourceExperimental — accuracy not yet measured
Sampson et al. 2016 does supply animal-model evidence that gut microbiota drive disease in a Parkinson's (α-synuclein overexpressing) mouse model via microglia: the SUMMARY (p. 3) reports 'gut microbiota are required for motor deficits, microglia activation, and αSyn pathology,' and the DISCUSSION (p. 10) links this to microbiota-dependent microglia maturation/activation by SCFAs. However, the source hedges the mechanism as 'one potential pathway' within mechanisms that are 'likely complex,' and the DISCUSSION (p. 11) explicitly posits other, undiscovered disease-modifying processes (autophagy, proteasome function) — so the claim's 'primarily through the modulation of microglial functions' overstates it. The generalization from a single synucleinopathy model to 'neurodegenerative disease pathogenesis' broadly is also beyond the paper, which only speculates that other amyloid disorders such as Alzheimer's and Huntington's 'may be impacted' (p. 11) and confines its conclusions to PD/synucleinopathies (pp. 10, 12). (LLM, conf=0.78)
- Partly supportedcites [56] Seo, D.-o et al. ApoE isoform- and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy. Science 379, eadd1236 (2023). sourceExperimental — accuracy not yet measured
Our copy of Seo et al. (Science 2023) is a mouse tauopathy study and does support the core of the claim: germ-free rearing and antibiotic-induced microbiota perturbation reduced gliosis, tau pathology and neurodegeneration, with the GF rescue reversed by fecoral colonization from conventionally-raised donors, and the paper concludes 'GF conditions affect microglia and astrocyte reactivity or activation associated with tau-mediated neurodegeneration' (sections 'TE4 Germ-free mice exhibit reduced reactive gliosis', 'Antibiotic-treatment alters astrocyte and microglial gene expression and morphological responses'). However, the claim's 'primarily through the modulation of microglial functions and activation' narrows the source wrongly: the paper implicates astrocytes at least as strongly (disease-associated astrocyte phenotypes, GFAP/Iba1/CD68 staining, snRNA-seq astrocyte and microglial subcluster shifts, SCFA effects) alongside peripheral immune and metabolic signalling. The effect is also bounded in ways the claim drops — it was sex- and ApoE-isoform-dependent (ABX protected male TE3 but largely not TE4/APOE4 mice), and the authors frame the mechanism as hypothesis ('we hypothesize that the gut microbiota regulates the brain's innate immune response', Conclusion) rather than settled 'compelling' causation across neurodegenerative disease generally. (LLM, conf=0.72)
- Partly supportedcites [57] Burberry, A. et al. C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature 582, 89–94 (2020). sourceExperimental — accuracy not yet measured
Our copy is an animal-model study that does support the core link: in the C9orf72Harvard loss-of-function mice, suppressing gut microflora with antibiotics or transplanting flora from a protective environment attenuated systemic and neural inflammation (Abstract; 'Antibiotics prevent inflammation'), and microglial pro-inflammatory markers Dectin1 and Ccr9 were significantly reduced by antibiotic treatment ('Environment governs neuroinflammation'). But the claim's 'primarily through the modulation of microglial functions and activation' is not what this paper concludes: its summary passage attributes the effect to both peripheral immune-cell infiltration of the spinal cord and microglial activation, and it explicitly found that microglial lysosomal markers (Lamp1, Cathepsin B) were NOT decreased by lifelong microbiota suppression, i.e. regulated 'independently from microbial signals'. The paper also hedges ('signals derived from gut bacteria promote inflammation and autoimmunity when C9orf72 function is diminished'; 'the microbiome may be an important governor') and confines this to C9orf72-related ALS/FTD in mice, noting the general microglia-maturation point belongs to other works it cites (ref 31, and refs 33-34 for Alzheimer's/Parkinson's models, Discussion). So the specific mechanism emphasis and the broad 'neurodegenerative disease pathogenesis' scope overstate this source. (LLM, conf=0.78)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Evidence has unveiled the bidirectional communication between the gut microbiome and the central nervous system, referred to as the “microbiota–gut–brain axis”.”
- Also stated in: § Introduction · boosted
“Accumulating evidence has unveiled the bidirectional communication between the gut microbiome and central nervous system (CNS), referred to as the “microbiota–gut–brain axis”.30,31”
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > Abstract
What the sources say
- Supportedcites [30] Ahmed, H. et al. Microbiota-derived metabolites as drivers of gut-brain communication. Gut Microbes 14, 2102878 (2022). source
The Introduction describes a bidirectional communication network between the central nervous system and intestine and says that gut microbiota signals the brain through it. The Enteric nervous system section also describes a loop of gut–brain–gut signaling. Together, these passages support the citing sentence’s description of the microbiota–gut–brain axis. (LLM, conf=0.92)
- Not checked yetcites [31] Morais, L. H., Schreiber, H. L. & Mazmanian, S. K. The gut microbiota–brain axis in behaviour and brain disorders. Nat. Rev. Microbiol. 19, 241–255 (2021). source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · boosted
254 more claims · 79 with their cited sources checked
Create a free account to see all 410 claims and to verify the 399 references still open.
- It may state two separate claims as one. 140
- Probably not a substantial claim. 18
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recent research has increasingly underscored the pivotal role of the gut microbiota in modulating the GBA.”
From The hidden genetic and microbial networks connecting neuropsychiatric and digestive disorders (2025) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > Microbiome-based therapeutics > Clinical applications of microbiome-based therapeutics
“| Probiotic sachets containing:- Bifidobacterium breve A1 (MCC1274) | AD | AD patients N = 60 (Control)N = 55 (Intervention)”
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > References
“778. Asaoka D Effect of probiotic Bifidobacterium breve in improving cognitive function and preventing brain atrophy in older patients with suspected mild cognitive impairment: results of a 24-week randomized, double-blind, placebo-controlled trial”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > Microbiome-based therapeutics > Probiotics and prebiotics
“| Probiotic suspension Symprove™ | DSP-4 and 6-OHDA-induced PD mice | Daily treatment for 24 days”
§ Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases > References
“760. Sancandi M Effects of a probiotic suspension Symprove™ on a rat early-stage Parkinson’s disease model”
Citations
Cites
1 retracted
Tamtaji, O. R., Taghizadeh, M., Daneshvar Kakhaki, R., Kouchaki, E., Bahmani, F., Borzabadi, S., Oryan, S., Mafi, A., & Asemi, Z. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.05.018 · Cited by 398
RetractedA human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592
Human gut microbiome viewed across age and geography
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012) · Nature · doi:10.1038/nature11053 · Cited by 7,815
Hallmarks of aging: An expanding universe
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2023) · Cell · doi:10.1016/j.cell.2022.11.001 · Cited by 6,549
Gibson, G. R., Hutkins, R., Sanders, M. E., Prescott, S. L., Reimer, R. A., Salminen, S. J., Scott, K., Stanton, C., Swanson, K. S., Cani, P. D., et al. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.75 · Cited by 5,634
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936
Cited by
Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy
Shen, Y., Fan, N., Ma, S., Cheng, X., Yang, X., & Wang, G. (2025) · MedComm · doi:10.1002/mco2.70168 · Cited by 301
Antibiotics and the gut microbiome: Understanding the impact on human health
Lathakumari, R. H., Vajravelu, L. K., Satheesan, A., Ravi, S. S. S., & Thulukanam, J. (2024) · Medicine in Microecology · doi:10.1016/j.medmic.2024.100106 · Cited by 182
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications
Pu, T., Sun, J., Ren, G., & Li, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02241-8 · Cited by 171
The Microbiota–Gut–Brain Axis and Neurological Disorders: A Comprehensive Review
Nakhal, M. M., Yassin, L. K., Alyaqoubi, R., Saeed, S., Alderei, A., Alhammadi, A., Alshehhi, M., Almehairbi, A., Houqani, S. A., BaniYas, S., et al. (2024) · Life · doi:10.3390/life14101234 · Cited by 154
Chen, C., Wang, G., Li, D., & Zhang, F. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00307-1 · Cited by 147
Metadata
- Authors
- Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y.
- Affiliations
- Monash University Malaysia (MY)
- Taylor's University (MY)
- UCL School of Pharmacy (GB)
- Corresponding author
- How, Chee Wun
- Khaw, Kooi Yeong
- ORCID
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-02-16
- Volume
- 9
- Issue
- 1
- Pages
- 37-37
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC10869798
- OpenAlex
- W4392783067
- Semantic Scholar
- c0e02114aa9a2a998ea241db2e5f6de2751e910e
- Cited by
- 1,193
- References
- 790
- Citations by year
- 2026: 551 · 2025: 509 · 2024: 131
- FWCI
- 48.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Greater South Information System
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- microbiota-gut-brain axis, gut microbiota, neurodegenerative diseases, glial cells, microglia, astrocytes, oligodendrocytes, gut microbiota metabolites, neurotransmitters, gastrointestinal hormones, intestinal barrier, blood-brain barrier, meninges, peripheral immune system, probiotics, prebiotics, fecal microbiota transplantation
- MeSH terms
- Brain-Gut Axis, Brain, Humans, Neurodegenerative Diseases, Probiotics, Prebiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. https://app.cochat.ai/papers/10.1038/s41392-024-01743-1
- The paper
- Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024). Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-024-01743-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.